Scarab Genomics adds Protein D vaccine carrier to its catalog

The success of conjugate vaccine technology, in which a highly immunogenic protein is linked to a poorly immunogenic antigen such as a small carbohydrate, is leading to the increased deployment of conjugate vaccines. However, once a patient is vaccinated with a conjugate vaccine, subsequent vaccination with other vaccines that use the same protein conjugate may elicit an immune response to the new vaccines, diminishing their effectiveness. To circumvent this problem, conjugate vaccines need to be developed using alternative protein conjugates. Therefore in addition to the original CRM197 conjugate protein offered, Scarab is pleased to announce the addition of Protein D to the catalog for immediate purchase.